Keyword Search Subscribe to receive breaking news alerts about uniQure. Subscribe Year None202420232022202120202019201820172016 Date Title Dec 10, 2024 uniQure Announces Alignment with FDA on Key Elements of Accelerated Approval Pathway for AMT-130 in Huntington’s Disease Nov 21, 2024 uniQure Announces Dosing of First Patient in GenTLE Phase I/IIa Clinical Trial of AMT-260 for the Treatment of Refractory Mesial Temporal Lobe Epilepsy Nov 05, 2024 uniQure Announces Third Quarter 2024 Financial Results and Highlights Recent Company Progress Oct 15, 2024 uniQure Announces Dosing of First Patient in Phase I/II Clinical Trial of AMT-162 for the Treatment of SOD1-ALS Sep 23, 2024 uniQure Announces Orphan Drug Designation Granted to AMT-191 for the Treatment of Fabry Disease Aug 15, 2024 uniQure Announces Dosing of First Patient in Phase I/IIa Clinical Trial of AMT-191 for the Treatment of Fabry Disease Pagination Current page 1 Page 2 Page 3 Next page next › Last page last »